Man's best friend: What can pet dogs teach us about non-Hodgkin's lymphoma?

Immunological Reviews

Volumn 263, Issue 1, 2015, Pages 173-191

  Richards, Kristy L ^a,b,c   Suter, Steven E ^a,b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Comparative oncology; Knockout mice; Lymph nodes; Molecular biology; Signal transduction

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD135 ANTIGEN; CELL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; REAGENT; VINCRISTINE;

ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANINE MODEL; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DOG; EXPERIMENTAL MODEL; EXTERNAL BEAM RADIOTHERAPY; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; BREEDING; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DISEASE MODEL; DOG DISEASES; GENOTYPE ENVIRONMENT INTERACTION; LYMPHOMA, NON-HODGKIN; MOLECULARLY TARGETED THERAPY; MOUSE; TREATMENT OUTCOME; VETERINARY;

ANIMALS; BREEDING; CHROMOSOME ABERRATIONS; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; GENE-ENVIRONMENT INTERACTION; HUMANS; LYMPHOMA, NON-HODGKIN; MICE; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84926409895     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12238     Document Type: Article

References (154)

1. Zullo K, Amengual JE, O'Connor OA, Scotto L. Murine models in mantle cell lymphoma. Best Pract Res Clin Haematol 2012;25:153-163.
2. Macor P, Secco E, Zorzet S, Tripodo C, Celeghini C, Tedesco F. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008;14:2023-2039.
3. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988;167:353-371.
4. Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol 2014;159:192-201.
5. Khanna C, et al. The dog as a cancer model. Nat Biotechnol 2006;24:1065-1066.
6. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16:351-380.
7. Lindblad-Toh K, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005;438:803-819.
8. Bronden LB, Flagstad A, Kristensen AT. Veterinary cancer registries in companion animal cancer: a review. Vet Comp Oncol 2007;5:133-144.
9. Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukemia and lymphoma. Bibl Haematol 1970;36:403-415.
10. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-318.
11. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002;43:240-246.
12. Shiels MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev 2013;22:1069-1078.
13. Modiano JF, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005;65:5654-5661.
14. Merlo DF, et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 2008;22:976-984.
15. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009;2009:591753.
16. Garber K. Lymphoma rate rise continues to baffle researchers. J Natl Cancer Inst 2001;93:494-496.
17. Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
18. Dorn CR, Taylor DO, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res 1967;28:993-1001.
19. Edwards DS, Henley WE, Harding EF, Dobson JM, Wood JL. Breed incidence of lymphoma in a UK population of insured dogs. Vet Comp Oncol 2003;1:200-206.
20. Ponce F, et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol 2010;47:414-433.
21. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980;54:1-210.
22. Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin's lymphoma. Vet Q 1994;16:209-219.
23. Lurie DM, Lucroy MD, Griffey SM, Simonson E, Madewell BR. T-cell-derived malignant lymphoma in the boxer breed. Vet Comp Oncol 2004;2:171-175.
24. Lurie DM, Milner RJ, Suter SE, Vernau W. Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed. Vet Immunol Immunopathol 2008;125:102-110.
25. Modiano JF, Breen M, Avery AC, London, CA. Breed specific canine lymphoproliferative diseases. In: Ostrander EA, Giger U, Lindblad-Toh K eds. The Dog and It's Genome. Cold Spring Harbor: Cold Spring Harbor Press, 2010:439-450.
26. LeBlanc AK. Cancer and comparative imaging. ILAR J 2014;55:164-168.
27. National Cancer Institute. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-2135.
28. Lennert KFA. Histopathology of Non-Hodkin's Lymphomas (Based on the Updated Kiel Classification). 2nd edn. Berlin: Springer-Verlag, 1990.
29. Valli VE, Jacobs RM, Parodi AL, Vernau W, Moore PF. Histologic Classification of Hematopoietic Tumors of Domestic Animals. Washington, DC: Armed Forces Institute of Pathology and the World Health Organization, 2002.
30. Valli VE, Kass PH, San Myint M, Scott F. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Vet Pathol 2013;50:738-748.
31. Vezzali E, Parodi AL, Marcato PS, Bettini G. Histopathological classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Vet Comp Oncol 2009;8:38-49.
32. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood 2006;107:1255-1264.
33. Wang SS, Vose JM. Epidemiology and prognosis of T-cell lymphoma. In: Foss F, ed. T-Cell Lymphomas. Contemporary Hematology. XV. New York: Springer Science+Business Media, 2013:25-39.
34. Chiou SH, Chow KC, Yang CH, Chiang SF, Lin CH. Discovery of Epstein-Barr virus (EBV)-encoded RNA signal and EBV nuclear antigen leader protein DNA sequence in pet dogs. J Gen Virol 2005;86(Pt 4):899-905.
35. Milman G, Smith KC, Erles K. Serological detection of Epstein-Barr virus infection in dogs and cats. Vet Microbiol 2011;150:15-20.
36. Chiu HC, et al. Expression of EBV-encoded oncogenes and EBV-like virions in multiple canine tumors. Vet Microbiol 2013;163:79-89.
37. Huang SH, et al. Evidence of an oncogenic gammaherpesvirus in domestic dogs. Virology 2012;427:107-117.
38. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990;9:125-136.
39. Daters AT, Mauldin GE, Mauldin GN, Brodsky EM, Post GS. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma. Vet Comp Oncol 2010;8:11-22.
40. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
41. MacEwen EG, Patnaik AK, Wilkins RJ. Diagnosis and treatment of canine hematopoietic neoplasms. Vet Clin North Am 1977;7:105-118.
42. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
43. Flood-Knapik KE, Durham AC, Gregor TP, Sanchez MD, Durney ME, Sorenmo KU. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol 2013;11:272-286.
44. Richards KL, et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res 2013;73:5029-5039.
45. Frantz AM, et al. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol 2013;50:693-703.
46. Brown EM, et al. A feasibility study of low-dose total body irradiation for relapsed canine lymphoma. Vet Comp Oncol 2006;4:75-83.
47. Laing EJ, et al. Half-body radiotherapy in the treatment of canine lymphoma. J Vet Intern Med 1989;3:102-108.
48. Rassnick KM, et al. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med 2007;21:1364-1373.
49. Gustafson NR, Lana SE, Mayer MN, LaRue SM. A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma. Vet Comp Oncol 2004;2:125-131.
50. Lurie DM, Gordon IK, Theon AP, Rodriguez CO, Suter SE, Kent MS. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma. J Vet Intern Med 2009;23:1064-1070.
51. Lurie DM, Kent MS, Fry MM, Theon AP. A toxicity study of low-dose rate half-body irradiation and chemotherapy in dogs with lymphoma. Vet Comp Oncol 2008;6:257-267.
52. Williams LE, Johnson JL, Hauck ML, Ruslander DM, Price GS, Thrall DE. Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703-709.
53. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-3613.
54. Jubala CM, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol 2005;42:468-476.
55. Ito D, Brewer S, Modiano JF, Beall MJ. Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk Lymphoma 2014;1-7. [Epub ahead of print].
56. Aratana Therapeutics I. Financial Statements and Exhibits, Ex-99.1. Washington, DC: U.S. Securities and Exchange Commission, 2014.
57. Zinzani PL, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012;53:789-795.
58. Artana Therapeutics, Inc. Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma [press release], 2014. London, UK: PR Newswire.
59. Rosales C, Jeglum KA, Obrocka M, Steplewski Z. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement. Cell Immunol 1988;115:420-428.
60. Stein R, et al. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 2011;52:273-284.
61. Steplewski Z, Rosales C, Jeglum KA, McDonald-Smith J. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies. In vivo 1990;4:231-234.
62. Singer J, et al. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther 2014;13:1777-1790.
63. Buckner D, Eisel R, Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood 1968;31:653-672.
64. Lee R, Storb R, Little MT, Joslyn A, Spector M, Kuhr CS. Percutaneous central dual-lumen catheter for apheresis in the canine. J Invest Surg 2002;15:337-341.
65. Deeg HJ, Appelbaum FR, Weiden PL, Hackman RC, Graham TC, Storb RC. Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation. Am J Vet Res 1985;46:2016-2018.
66. Weiden PL, Storb R, Deeg HJ, Graham TC. Total body irradiation and autologous marrow transplantation as consolidation therapy for spontaneous canine lymphoma in remission. Exp Hematol 1979;7(Suppl 5):160-163.
67. Weiden PL, Storb R, Sale GE, Graham TC, Thomas ED. Allogeneic hematopoietic grafts after total-body irradiation in dogs with spontaneous tumors. J Natl Cancer Inst 1978;61:353-357.
68. Appelbaum FR, Deeg HJ, Storb R, Graham TC, Charrier K, Bensinger W. Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. Transplantation 1986;42:19-22.
69. Weiden PL, Storb R, Deeg HJ, Graham TC, Thomas ED. Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions. Blood 1979;54:1039-1049.
70. Lupu M, Gooley T, Zellmer E, Graves SS, Storb R. Principles of peripheral blood mononuclear cell apheresis in a preclinical canine model of hematopoietic cell transplantation. J Vet Intern Med 2008;22:74-82.
71. Suter SE. Collection of peripheral blood CD34+ progenitor cells from healthy dogs and dogs diagnosed with lymphoproliferative diseases using a Baxter-Fenwal CS-3000 Plus blood cell separator. J Vet Intern Med 2011;25:1406-1413.
72. Bodenberger U, et al. Fractionated total body irradiation and autologous bone marrow transplantation in dogs: hemopoietic recovery after various marrow cell doses. Exp Hematol 1980;8:384-394.
73. Escobar C, Grindem C, Neel JA, Suter SE. Hematologic changes after total body irradiation and autologous transplantation of hematopoietic peripheral blood progenitor cells in dogs with lymphoma. Vet Pathol 2012;49:341-343.
74. Willcox JL, Pruitt A, Suter SE. Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma. J Vet Intern Med 2012;26:1155-1163.
75. Warry EE, Willcox JL, Suter SE. Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma. J Vet Intern Med 2014;28:529-537.
76. Frimberger AE, Moore AS, Rassnick KM, Cotter SM, O'Sullivan JL, Quesenberry PJ. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006;20:355-364.
77. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2011. doi:10.1111/j.1476-5829.2011.00283.x.
78. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2013;12032:1-8.
79. Vail DM, Michels GM, Khanna C, Selting KA, London CA. Veterinary Cooperative Oncology G. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2010;8:28-37.
80. Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 2009;6:e1000161.
81. Paoloni MC, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE 2009;4:e4972.
82. Paoloni M, Lana S, Thamm D, Mazcko C, Withrow S. The creation of the comparative oncology trials consortium pharmacodynamic core: infrastructure for a virtual laboratory. Vet J 2010;185:88-89.
83. Vail DM. Comparative oncology - the North American experience. BMC Proc 2013;7(Suppl):K5.
84. Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematology 2008;22:807-823, vii.
85. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosome Res 2008;16:145-154.
86. Thomas R, et al. Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma 2011;52:1321-1335.
87. Derrien T, Andre C, Galibert F, Hitte C. AutoGRAPH: an interactive web server for automating and visualizing comparative genome maps. Bioinformatics 2007;23:498-499.
88. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
89. Mudaliar MA, et al. Comparative gene expression profiling identifies common molecular signatures of NF-kappaB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS ONE 2013;8:e72591.
90. Paoloni M, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genom 2009;10:625.
91. Scott MC, et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 2011;49:356-367.
92. Su Y, et al. Gene selection and cancer type classification of diffuse large-B-cell lymphoma using a bivariate mixture model for two-species data. Human Genom 2013;7:2.
93. Comazzi S, Gelain ME. Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. Vet J 2011;188:149-155.
94. Wilkerson MJ, et al. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Vet Immunol Immunopathol 2005;106:179-196.
95. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
96. Nowakowski GS, et al. Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase 2 study. 2014 ASCO Annual Meeting; Chicago, IL. J Clin Oncol 2014 [Epub ahead of print].
97. Ruan J, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
98. Thieblemont C, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079-4087.
99. Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology 2013;2013:584-590.
100. Coutinho R, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res 2013;19:6686-6695.
101. Sato M, et al. Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma. Vet J 2012;191:108-114.
102. Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol 2013;20:315-326.
103. Nguyen F, Fourel J, Moreau AA, Le Gouill S, Davodeau F, editors. Canine Lymphoma as a Spontaneous Model in Oncology: Special Emphasis on DLBCLs. INCa Workshop, Spontaneous tumours in dogs: Nosology conference for 4 tumour types; 2014; Nantes, France.
104. Chen HW, Small GW, Motsinger-Reif A, Suter SE, Richards KL. VH1-44 gene usage defines a subset of canine B-cell lymphomas associated with better patient survival. Vet Immunol Immunopathol 2014;157:125-130.
105. Lossos IS, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209-10213.
106. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008;45(3 Suppl 2):S17-S21.
107. Suter SE, Small GW, Seiser EL, Thomas R, Breen M, Richards KL. FLT3 mutations in canine acute lymphocytic leukemia. BMC Cancer 2011;11:38.
108. Gasparini C, Celeghini C, Monasta L, Zauli G. NF-kappaB pathways in hematological malignancies. Cell Mol Life Sci 2014;71:2083-2102.
109. Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ. NEMO-binding domain peptide inhibits constitutive NF-kappaB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:4661-4671.
110. Habineza Ndikuyeze G, et al. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. PLoS ONE 2014;9:e95404.
111. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23:410-421.
112. Maddocks K, Blum KA. Ibrutinib in B-cell lymphomas. Curr Treat Options Oncol 2014;15:226-237.
113. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075-13080.
114. Voutsadakis IA. Apoptosis and the pathogenesis of lymphoma. Acta Oncol 2000;39:151-156.
115. Uhl E, Krimer P, Schliekelman P, Tompkins SM, Suter S. Identification of altered MicroRNA expression in canine lymphoid cell lines and cases of B- and T-Cell lymphomas. Genes Chromosom Cancer 2011;50:950-967.
116. He L, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833.
117. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996;95:513-517.
118. Thomas A, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
119. Oricchio E, et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J Exp Med 2014;211:1379-1391.
120. Monti S, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell 2012;22:359-372.
121. Fosmire SP, et al. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Vet Pathol 2007;44:467-478.
122. Modiano JF, Breen M, Valli VE, Wojcieszyn JW, Cutter GR. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007;21:184-187.
123. Parker HG, et al. Genetic structure of the purebred domestic dog. Science 2004;304:1160-1164.
124. Seiser EL, et al. Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines. Vet Comp Oncol 2013;11:30-50.
125. Ito D, et al. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma 2012;53:1390-1398.
126. Hoeppner MP, et al. An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts. PLoS ONE 2014;9:e91172.
127. Emenaker N, Kagan J. Biomarkers and "Omics". In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. 1, 7th ed. St. Louis, MO: Saunders; 2010:2117-2120.
128. Ghernati I, et al. Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sezary syndrome and producing retroviral particles. Leukemia 1999;13:1281-1290.
129. Ito D, et al. A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med 2011;25:890-896.
130. Kisseberth WC, et al. A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res 2007;31:1709-1720.
131. Rutgen BC, et al. Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. PLoS ONE 2012;7:e40078.
132. Umeki S, et al. Establishment of five canine lymphoma cell lines and tumor formation in a xenotransplantation model. J Vet Intern Med 2013;75:467-474.
133. Argyle DJ, Madewell BR. A landmark in veterinary and comparative oncology. Vet Comp Oncol 2003;1:1-2.
134. Comazzi S, Guscetti F, Marconato L. First meeting of the European canine lymphoma group. Workshop: state of the art and comparative aspects in canine lymphoma. CH-Lugano, 22 June 2013. Hematol Oncol 2013;32:68-71.
135. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011;477:526-528.
136. Mack GS. Clinical trials going to the dogs: canine program to study tumor treatment, biology. J Natl Cancer Inst 2006;98:161-162.
137. Fiocchi SC, Selting KA, Rosenberg MP, Kolli P, Lenaz G, Henry C. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs. J Vet Intern Med 2011;25:897-902.
138. Gavazza A, et al. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 2013;24:728-738.
139. Griessmayr PC, Gauthier M, Barber LG, Cotter SM. Mushroom-derived maitake PETfraction as single agent for the treatment of lymphoma in dogs. J Vet Intern Med 2007;21:1409-1412.
140. Henson MS, et al. Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma. Vet Comp Oncol 2011;9:95-105.
141. London CA, et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS ONE 2014;9:e87585.
142. Marconato L, et al. Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clin Cancer Res 2014;20:668-677.
143. Meier V, Geigy C, Grosse N, McSheehy P, Rohrer Bley C. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs. J Vet Intern Med 2013;27:120-125.
144. Vail DM, et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:3503-3510.
145. Silver M, et al. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma. J Vet Intern Med 2012;26:349-354.
146. Rusk A, et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 2006;12:7456-7464.
147. Nakaichi M, et al. Establishment and characterization of a new canine B-cell leukemia cell line. J Vet Intern Med 1996;58:469-471.
148. Momoi Y, Okai Y, Watari T, Goitsuka R, Tsujimoto H, Hasegawa A. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet Immunol Immunopathol 1997;59:11-20.
149. Rutgen BC, et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 2010;34:932-938.
150. Holmes MA, Duffus WP, Gorman NT. Natural cytotoxicity in the dog: description of two new allogeneic tumour targets. Vet Immunol Immunopathol 1989;23:161-170.
151. Strandstrom HV, Rimaila-Parnanen E. Canine atypical malignant lymphoma. Am J Vet Res 1979;40:1033-1034.
152. Suter SE, et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res 2005;11:1579-1587.
153. Steplewski Z, Jeglum KA, Rosales C, Weintraub N. Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer Immunol Immunother 1987;24:197-201.
154. COTC. https://ccrod.cancer.gov/confluence/display/CCRCOPWeb/Comparative+Oncology+Trials+Consortium. 2014.